PTJ
OREX

Paul Tudor Jones’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Paul Tudor Jones’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,207
Closed -$5K – 1922
2016
Q2 		$5K Sell
1,207
-6,440
-84% -$29.1K ﹤0.01% 1579
2016
Q1 		$43K Sell
7,647
-2,497
-25% -$32.4K ﹤0.01% 1661
2015
Q4 		$174K Buy
10,144
+9,028
+809% +$215K ﹤0.01% 1460
2015
Q3 		$24K Sell
1,116
-304
-21% -$10.4K ﹤0.01% 1492
2015
Q2 		$70K Sell
1,420
-2,283
-62% -$136K ﹤0.01% 1432
2015
Q1 		$290K Buy
+3,703
New +$230K 0.01% 1070
2014
Q1 		– Sell
-1,192
Closed -$67K – 1625
2013
Q4 		$67K Buy
+1,192
New +$67K ﹤0.01% 1224

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Paul Tudor Jones's OREX Position: Q3 2016 in Review

Paul Tudor Jones sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 1,207 shares — an estimated $5K sold.

Paul Tudor Jones first reported a position in OREX in Q4 2013 and held it in 7 quarters. The position peaked at $290K in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Paul Tudor Jones reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Paul Tudor Jones sold 1,207 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $5K.
  • Paul Tudor Jones first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 7 quarters.
  • Paul Tudor Jones's Orexigen Therapeutics, Inc. position peaked at $290K in Q1 2015.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Tudor Investment Corp's 13F filing for Q3 2016, filed 14 Nov 2016.